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2012;60:2631–9.Duration of Triple Therapy
in Patients Requiring
Oral Anticoagulation After
Drug-Eluting
Stent ImplantationTABLE 1 Stent Types Used in the ISAR-TRIPLE Trial
6 Weeks of
Therapy
(n ¼ 417)
6 Months
of Therapy
(n ¼ 409)
First-generation DES (SES, PES) 29 (6) 16 (4)
Second-generation DES (EES, ZES) 203 (49) 206 (50)
BA-DES, BD-DES, DES-Ab, DEB 183 (44) 186 (45)
Values are n (%).
BA-DES ¼ bioabsorbable-drug eluting stent(s); BD-DES ¼ biodegradable
drug-eluting stent(s); DEB ¼ drug-eluting balloon; DES ¼ drug-eluting stent(s);
DES-Ab ¼ Abluminal biodegradable polymer metallic drug-eluting stent(s); EES ¼
everolimus-eluting stent(s); ISAR-TRIPLE ¼ Duration of Triple Therapy in Patients
Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation; PES ¼
paclitaxel-eluting stent(s); SES ¼ sirolimus-eluting stent(s); ZES ¼ zotarolimus-
eluting stent(s).We read with much interest the paper and editorial by
Fiedler et al. (1) and Bhatt et al. (2) regarding the
optimal duration of dual antiplatelet therapy (DAPT)
in patients on systemic anticoagulation in a recent
issue of the Journal. In this randomized, open-label
trial, 614 patients underwent drug-eluting stent
(DES) implantation and were randomized to either
6 weeks or 6 months of clopidogrel therapy. They
found no difference in the primary endpoint
(composite of death, myocardial infarction, deﬁnite
stent thrombosis, stroke, or TIMI [Thrombolysis In
Myocardial Infarction] major bleeding) between
the 2 groups (9.8% vs. 8.8%; p ¼ 0.63). In addition,
the secondary combined ischemic endpoint of
cardiac death, myocardial infarction, deﬁnite stent
thrombosis, and ischemic stroke was no different
(4.0% vs. 4.3%; p ¼ 0.87), and there was also no
difference in the TIMI major bleeding between the
groups.Despite the important ﬁndings of this study,
some concerns remain unanswered that may limit the
broader clinical application of the results of this
study. The investigators used a large number of stent
types in this study including ﬁrst-generation, second-
generation, and newer-generation (bioabsorbable/
degradable) DES (Table 1). In summary, $44% of the
stents implanted in the study included newer-
generation DES (bioabsorbable/biodegradable stents).
These could potentially affect the efﬁcacy and safety
of this strategy when applied to a larger unrestricted
population.
There was an increased risk of stent thrombosis
with ﬁrst-generation DES that led to the development
of DES with biocompatible polymers and more re-
cently biodegradable polymers and bioabsorbable
vascular scaffolds. We have shown compelling data
for safety and efﬁcacy of second-generation DES
with biocompatible polymers in a large spectrum
of patients including those at high risk for stent
thrombosis (3). The newer DES with bioabsorbable/
biodegradable polymers and stents that allow for
complete dissolution of polymer or bioscaffold
leaving either a residual metal platform or native
vessel would, in theory, reduce the rates of stent
thrombosis. Biodegradable polymer biolimus-eluting
stents were perceived to be safer than ﬁrst-
generation sirolimus-eluting stents on the basis of
the results of individual trials that were powered for
only composite endpoints of safety and efﬁcacy.
However, in the largest mixed comparison meta-
analysis of >61 trials involving 63,242 patients, there
was a signiﬁcant increase in the odds of myocardial
infarction (1.29; 95% conﬁdence interval: 1.02 to 1.69)
with the use of biodegradable polymer DES versus
the second-generation DES at 1 year (4). In fact, the
second-generation DES was associated with the most
favorable safety proﬁle. Additionally, another mixed
comparison meta-analysis that included 77 studies
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1089including 75,484 patients concluded that both
early and late stent thrombosis were higher in
the biodegradable polymer groups over second-
generation DES. These ﬁndings may partially explain
the higher rate of myocardial infarction in the
6-weeks DAPT group (5).
Given the unequivocal nature of the current data,
it is important to understand these individual
endpoints on a stent level. Whereas a strategy of a
shorter duration of DAPT may be reasonable in
second-generation DES, a longer duration of DAPT
will likely be needed in the bioabsorbable/degradable
stent platforms.*Femi Philip, MD
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2014;35:1147–58.REPLY: Duration of Triple Therapy in
Patients Requiring Oral Anticoagulation
After Drug-Eluting Stent ImplantationWe appreciate the comments of Dr. Philip regarding
the results of our ISAR-TRIPLE (Duration of Triple
Therapy in Patients Requiring Oral Anticoagulation
After Drug-Eluting Stent Implantation) trial (1). We
could not ﬁnd a signiﬁcant difference in clinical
outcomes between a 6-week and a 6-month triple
therapy duration in patients who received drug-
eluting stents (DES) and had an indication for
oral anticoagulation. Dr. Philip is concerned that a
shorter triple therapy might not apply to biodegradablepolymer (BP)-based DES (BP-DES) or fully bioresorbable
DES. In Dr. Philip’s opinion, on the basis of the results
of 2 network meta-analyses, BP-DES, when compared
with second-generation DES, are associated with an
increased risk for stent thrombosis and/or myocardial
infarction and, consequently, may need a longer
therapy duration. Our study certainly lacks the
power to look at differential treatment effects in
subgroups deﬁned by the type of DES used.
However, 3 of the 6 cases that incurred myocardial
infarction in the 6-week therapy group had received
new-generation everolimus-eluting stents (EES). In
total, there was no signiﬁcant interaction between
the use of BP-DES or EES and duration of triple
therapy regarding ischemic events. Moreover, with
only 6 patients (7 lesions) with fully bioresorbable
stents, we cannot make any statement about the
optimal triple therapy duration for this particular
device.
We would also like to highlight 3 more points.
First, categorization of DES into ﬁrst- and second-
generation or biodegradable polymer and permanent
polymer groups does not necessarily mean that the
devices included in each of these categories are
equally safe and effective. We have previously shown
that BP-DES with limited representation in the 2
meta-analyses cited by Dr. Philip show superior re-
sults to sirolimus-eluting stents at 4 years (2) and
equivalent results to EES at 5 years (3). Second,
direct comparative randomized trials (and meta-
analyses of these direct comparisons) constitute
the highest level of evidence to guide our patient
care. Where direct comparative randomized trials
exist, their role cannot be supplanted by indirect
comparison network meta-analyses irrespective
of how sophisticated they are. Speciﬁcally, 2 ran-
domized trials of BP-DES versus EES (4,5) are the
only relevant direct comparison trials included in
the 2 network meta-analyses quoted by Dr. Philip.
Neither trial showed differences between BP-DES
and EES regarding both stent thrombosis and
myocardial infarction (p $0.18). A simple pooling
together of these 2 studies, which enrolled a total of
5,942 patients, will yield a 1-year incidence of
myocardial infarction of 3.0% in the BP-DES group
and 2.9% in the EES group as well as an incidence of
deﬁnite and probable stent thrombosis of 0.5% in
the BP-DES group and 0.4% in the EES group (4,5).
Thus, the direct comparison randomized trials do
not support the existence of a signiﬁcant safety
disadvantage of BP-DES versus EES. Finally,
awareness of an excess thrombotic risk with a
certain DES among the multitude of DES that are
currently available should reasonably lead to the
